Despite the association between hypertriglyceridaemia and ASCVD risk, current triglyceride-lowering strategies have not conclusively demonstrated clinical outcome benefits.
No triglyceride-lowering therapy has shown conclusive outcome benefit; leaves open whether novel agents can reduce atherosclerotic risk.
The prevalence of hypertriglyceridaemia is high and growing in several parts of the world. Hypertriglyceridaemia has a well-defined association with the risk of atherosclerotic cardiovascular (CV) disease and triglycerides represent a potential target for drugs aimed at mitigating CV risk. So far, no triglyceride-lowering pharmacological strategy has succeeded in conclusively showing the ability to modify clinical outcomes. This article discusses strategic and clinical aspects of development of triglyceride-lowering drugs to address CV disease.
No takes yet. Share an insight, caveat, or question.
Hallén et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: